Nuvectis Pharma, Inc. (NVCT): R&D Expense
$18.15M
Year ended 2025-12-31
$19.65M
Trailing 12 months to 2026-06-30
+11.1%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $18.15M | +40.5% | 2026-02-11, From 2025-01-01 |
| 2024-12-31 | $12.92M | -16.0% | 2026-02-11, From 2024-01-01 |
| 2023-12-31 | $15.38M | +16.3% | 2025-02-25, From 2023-01-01 |
| 2022-12-31 | $13.23M | +38.6% | 2024-03-05, From 2022-01-01 |
| 2021-12-31 | $9.54M | n/a | 2023-03-08, From 2021-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | 2025-12-31 | $18.15M | +40.5% |
| Valion Bio, Inc. (VBIO) | 2025-12-31 | $3.13M | +138.5% |
| Equillium, Inc. (EQ) | 2025-12-31 | $12.84M | -65.7% |
| Tvardi Therapeutics, Inc. (TVRD) | 2025-12-31 | $18.01M | -23.8% |
| China Pharma Holdings, Inc. (CPHI) | 2025-12-31 | $280.9K | -1.1% |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | $5.52M | -61.4% |
| PDS Biotechnology Corp (PDSB) | 2025-12-31 | $19.03M | -15.7% |
| Yarrow Bioscience, Inc. (YARW) | 2025-12-31 | $19.24M | -37.8% |
| Sunshine Biopharma Inc. (SBFM) | 2025-12-31 | $604.3K | -35.3% |
Compare NVCT, VBIO, EQ, TVRD side by side · Screen every company in Pharmaceutical Preparations ↗